Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | PREP | P48147 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16250267 | 1.00 | SIGMAR1 (0.51) | SIGMAR1PREPSMN1; SMN2NPC1RAB9A | |
| SCHEMBL16250272 | 0.88 | PREP (0.47) | PREPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL17722317 | 0.88 | PREP (0.47) | PREPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL1190472 | 0.83 | PREP (0.49) | SIGMAR1PREPSMN1; SMN2NPC1RAB9A | |
| SCHEMBL15218168 | 0.79 | HTR2C (0.49) | PREPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL16237927 | 0.78 | OPRK1 (0.41) | SIGMAR1 | |
| SCHEMBL17768436 | 0.78 | OPRK1 (0.41) | SIGMAR1 | |
| SCHEMBL30477418 | 0.77 | SMN1; SMN2 (0.53) | PREPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL15185105 | 0.77 | SIGMAR1 (0.52) | SIGMAR1PREPSMN1; SMN2NPC1RAB9A | |
| SCHEMBL10169571 | 0.77 | PREP (0.54) | PREPSMN1; SMN2NPC1RAB9AACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160122307-A1 | PERHYDROQUINOXALINE DERIVATIVES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2016-05-05 | — | — | US | disclosed |
| US-8927566-B2 | Norepinephrine and selective serotonin receptor blocker and use thereof | BEIJING MEDISAN TECHNOLOGY CO., LTD. (CN) | 2015-01-06 | — | — | US | disclosed |
| WO-2014184355-A1 | PERHYDROQUINOXALINE DERIVATIVES USEFUL AS ANALGESICS | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122307-A1 | PERHYDROQUINOXALINE DERIVATIVES | PTGS1, HPGD, HMOX1 | SIGMAR1 624/4885PREP 556/4885SMN1; SMN2 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.